Literature DB >> 16785831

GI risk and risk factors of NSAIDs.

Loren Laine1.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs in the United States. Ulcers are found at endoscopy in 15% to 30% of patients using NSAIDs regularly. The annual incidence of upper gastrointestinal (GI) complications such as bleeding with regular NSAID use is approximately 1.0% to 1.5%, whereas the annual rate of upper GI clinical events (complicated plus symptomatic uncomplicated ulcers) is approximately 2.5% to 4.5%. Upper GI symptoms such as dyspepsia also occur in many patients taking NSAIDs--at a relative risk of about 1.5 to 2 compared with that in patients without NSAID use. Important risk factors for upper GI clinical events include older age, prior history of upper GI events, use of corticosteroids or anticoagulants, and high-dose or multiple NSAIDs (including NSAID plus low-dose aspirin). Lower GI clinical events such as bleeding may also occur with NSAIDs, although they are less common and less well studied than upper GI events. The decision to employ a protective strategy to decrease NSAID-associated GI clinical events is based on risk stratification. Strategies employed include the use of non-NSAID analgesics, use of lowest effective dose of NSAID, use of medical cotherapy (eg, proton pump inhibitor, misoprostol), or use of coxibs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785831     DOI: 10.1097/00005344-200605001-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  18 in total

1.  Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.

Authors:  Rahel Häuptle; Daniel Weilenmann; Tino Schneider; Sarah R Haile; Peter Ammann; Christina Knellwolf; Jan Borovicka
Journal:  Wien Med Wochenschr       Date:  2012-02

2.  DUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug.

Authors:  Alfonso E Bello
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

3.  Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.

Authors:  Ying He; Esther W Chan; Kenneth K C Man; Wallis C Y Lau; Wai K Leung; Lai M Ho; Ian C K Wong
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

4.  Sildenafil, an inhibitor of phosphodiesterase subtype 5, prevents indomethacin-induced small-intestinal ulceration in rats via a NO/cGMP-dependent mechanism.

Authors:  Naho Kato; Yuji Mashita; Shinichi Kato; Shoji Mitsufuji; Toshikazu Yoshikawa; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2008-12-20       Impact factor: 3.199

5.  Prevention and Treatment of NSAID Gastropathy.

Authors:  Carla J Gargallo; Carlos Sostres; Angel Lanas
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

Review 6.  The risk of gastric cancer in patients with duodenal and gastric ulcer: research progresses and clinical implications.

Authors:  Zunwu Zhang
Journal:  J Gastrointest Cancer       Date:  2007

7.  Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Authors:  Nicholas Latimer; Joanne Lord; Robert L Grant; Rachel O'Mahony; John Dickson; Philip G Conaghan
Journal:  BMJ       Date:  2009-07-14

8.  The effects of bariatric surgery weight loss on knee pain in patients with osteoarthritis of the knee.

Authors:  Christopher Edwards; Ann Rogers; Scott Lynch; Tamara Pylawka; Matthew Silvis; Vernon Chinchilli; Timothy Mosher; Kevin Black
Journal:  Arthritis       Date:  2012-12-03

Review 9.  The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.

Authors:  Anne Tuskey; David Peura
Journal:  Arthritis Res Ther       Date:  2013-07-24       Impact factor: 5.156

Review 10.  Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity.

Authors:  L McEvoy; D F Carr; M Pirmohamed
Journal:  Front Pharmacol       Date:  2021-06-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.